NASDAQ: CAPR - Capricor Therapeutics, Inc.

半年間の収益性: +198.31%
セクタ: Healthcare

プロモーションスケジュール Capricor Therapeutics, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

さらに詳しく
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2007-02-13
ISIN US14070B3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.capricor.com
Цена ао 4.19
1日あたりの価格変動: 0% (14.08)
週ごとの価格変動: +7.73% (13.07)
月ごとの料金変更: -26.05% (19.04)
3ヶ月間の価格変動: +41.51% (9.95)
半年間の価格変動: +198.31% (4.72)
年間の価格変動: +187.93% (4.89)
3年間の価格推移: +335.91% (3.23)
5年間の価格推移: +665.22% (1.84)
10年間の価格推移: 0% (14.08)
年初からの価格変動: -6.63% (15.08)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 4.73 3
P/BV 5.27 2
P/E 0 0
EV/EBITDA -4.78 0
合計: 4.38

効率

名前 意味 学年
ROA, % -37.95 0
ROE, % -98.61 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.2439 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 2417.81 10
収益性 Ebitda, % 194.99 10
収益性 EPS, % -58.18 0
合計: 8
さらに詳しく

機関 音量 共有, %
Vanguard Group Inc 1165404 3.7
Woodline Partners LP 909542 2.89
Blackrock Inc. 359673 1.14
Geode Capital Management, LLC 316198 1
Susquehanna International Group, LLP 149115 0.47
Renaissance Technologies, LLC 146321 0.46
Northern Trust Corporation 127229 0.4
Osaic Holdings Inc 116550 0.37
State Street Corporation 85224 0.27
Bank Of New York Mellon Corporation 84759 0.27

ETF 共有, % 年間の利益率, % 配当金, %
iShares Neuroscience and Healthcare ETF 0.2793 19.72 0.03
iShares Micro-Cap ETF 0.03249 13.79 1.54048
Vanguard Russell 2000 Growth ETF 0.01 17.39 0.60264
iShares Russell 2000 Growth ETF 0.00807 38.04 0.6026
ProShares UltraPro Russell2000 0.00277 89.82 1.47873
ProShares Hedge Replication ETF 0.0008 5.92 1.47892
Vanguard Russell 2000 ETF 0 14.37 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



スーパーバイザー 役職 支払い 生年
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (69 年)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (62 年)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (39 年)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (72 年)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

住所: United States, San Diego. CA, 10865 Road to the Cure - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.capricor.com